Cagrilintide

Main evidence: Human clinical trials. Updated 2026-10-28.

What research and users report, not a recommendation or medical advice. Many of these products are not approved for human use. Ask your doctor. Packs report what sources say, each with its evidence label. A claim labelled community, educator, manufacturer or animal has not been validated in humans.

Summary

This pack organizes cited evidence, protocol context, safety cautions, and Australian legal status for Cagrilintide.

What the sources say

In REDEFINE 1, 68-week mean weight change under the treatment-policy estimand was −20.4% with CagriSema, −11.5% with cagrilintide alone, −14.9% with semaglutide alone and −3.0% with placebo; this is evidence for the tested combination and trial population. (Human clinical trials; Garvey et al., Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1), 2025-06-22)
In a 32-week phase 2 trial in type 2 diabetes, CagriSema reduced mean body weight by 15.6%, compared with 8.1% for cagrilintide alone and 5.1% for semaglutide alone; mean HbA1c changes were −2.2, −0.9 and −1.8 percentage points, respectively. (Human clinical trials; Frias et al., Efficacy and safety of co-administered once-weekly cagrilintide and semaglutide in type 2 diabetes: phase 2 trial, 2023-06-23)
Cagrilintide is a long-acting amylin analogue with phase 2 monotherapy evidence for weight management; the CagriSema combination has separate human trial evidence and should not be conflated with cagrilintide alone. (Human clinical trials; Lau et al., Once-weekly cagrilintide for weight management in people with overweight and obesity: phase 2 trial, 2021-11-16)
In a 26-week phase 2 obesity study, once-weekly subcutaneous cagrilintide produced mean weight reductions of 6.0–10.8% across the studied dose arms versus 3.0% with placebo; the highest studied monotherapy arm had a 10.8% mean reduction versus 9.0% with liraglutide. (Human clinical trials; Lau et al., Once-weekly cagrilintide for weight management in people with overweight and obesity: phase 2 trial, 2021-11-16)
A Reddit poster described adding cagrilintide to retatrutide because appetite suppression felt insufficient and reported greater fullness; replies included fatigue, difficulty eating and low mood. Product identity, dose accuracy, causation and comparative benefit were not verified. (Community reports; Reddit r/Retatrutide, "If you're thinking of stacking Cagri with Reta do it" (page displayed "8mo ago"; accessed 2026-10-28), 2026-10-28)
In the phase 2 monotherapy study, gastrointestinal adverse events occurred in 41–63% of cagrilintide groups versus 32% with placebo, and nausea occurred in 20–47% versus 18%; these trial rates do not predict an individual response. (Human clinical trials; Lau et al., Once-weekly cagrilintide for weight management in people with overweight and obesity: phase 2 trial, 2021-11-16)
The Reddit combination report is uncontrolled and includes self-reported fatigue and difficulty eating; it cannot establish that cagrilintide caused those effects or that stacking is safe. (Community reports; Reddit r/Retatrutide, "If you're thinking of stacking Cagri with Reta do it" (page displayed "8mo ago"; accessed 2026-10-28), 2026-10-28)
The TGA warns that unapproved peptide products may not have been assessed for safety, quality or effectiveness and may be incorrectly labelled or non-sterile; this is a product-quality warning, not an adverse-event rate for trial cagrilintide. (Educator material (not peer reviewed); Therapeutic Goods Administration, Peptide products (last updated 2026-09-23), 2026-09-23)
As of 2026-10-28, no TGA registration for cagrilintide or CagriSema was identified in the public ARTG search; this is a search finding, not a determination about access through an authorized clinical trial or other lawful pathway. (Educator material (not peer reviewed); Therapeutic Goods Administration, Peptide products (last updated 2026-09-23), 2026-09-23)
The TGA states that therapeutic peptide products not included in the ARTG have not been evaluated for safety, quality or effectiveness and that unlawful importation, supply or advertising may attract penalties. (Educator material (not peer reviewed); Therapeutic Goods Administration, Peptide products (last updated 2026-09-23), 2026-09-23)

Sources

Dosing, stacking and protocol details are not published here.